It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The present study aimed to evaluate the outcomes of percutaneous treatment of aortic coarctation using self-expandable uncovered Nitinol stents. We conducted a retrospective clinical data review of all patients with aortic coarctation and treated with self-expandable uncovered Nitinol stents at our institution between 2009 and 2019. The gradient pressure across the coarctation site was measured using aortography. Follow-up echocardiography and computed tomography angiography were performed to assess possible stent complications. A total of 127 stents were successfully implanted in 125 patients (64.8% males) with a mean age of 35.36 ± 11.9 years. The gradient across the coarctation site decreased significantly from 67.48 ± 14.79 to 5.04 ± 3.01 mmHg (P < 0.001) after self-expandable stent implantation. Systolic blood pressure (SBP) decreased significantly from 175.53 ± 15.99 to 147.22 ± 12.83 mmHg (P < 0.001) after self-expandable stenting. There were no major technical or clinical complications, including balloon rupture, aneurysmal formation, infection, secondary stent migration, thrombosis, death during the procedure, and in-hospital mortality. On a mean follow-up of 48 ± 23.6 months (12–120 months), the gradient [from 59.43 ± 15.42 to 3.72 ± 1.38 mmHg (P < 0.001)] and SBP [from 175.53 ± 15.99 to 127.99 ± 7.82 mmHg (P < 0.001)] decreased significantly. There was no mortality, aneurysmal formation in the stent site, dislocation, or aortic re-stenosis requiring intervention during mid-term follow-up. Treatment of aortic coarctation using a self-expandable uncovered nitinol stent is safe and effective with promising mid-term outcomes.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Mashhad University of Medical Sciences, Department of Cardiovascular Diseases, Faculty of Medicine, Mashhad, Iran (GRID:grid.411583.a) (ISNI:0000 0001 2198 6209)
2 Islamic Azad University, Tehran, Iran (GRID:grid.411463.5) (ISNI:0000 0001 0706 2472)
3 Mashhad University of Medical Sciences, Department of Cardiovascular Diseases, Faculty of Medicine, Mashhad, Iran (GRID:grid.411583.a) (ISNI:0000 0001 2198 6209); Mashhad University of Medical Sciences, Vascular and Endovascular Surgery Research Center, Mashhad, Iran (GRID:grid.411583.a) (ISNI:0000 0001 2198 6209)
4 Mashhad University of Medical Sciences, Division of Congenital and Pediatric Cardiology, Department of Pediatrics, Faculty of Medicine, Mashhad, Iran (GRID:grid.411583.a) (ISNI:0000 0001 2198 6209)
5 Mashhad University of Medical Sciences, Clinical Research Development Unit, Imam Reza Hospital, Mashhad, Iran (GRID:grid.411583.a) (ISNI:0000 0001 2198 6209)
6 Mashhad University of Medical Sciences, Pharmacological Research Center of Medicinal Plants, Mashhad, Iran (GRID:grid.411583.a) (ISNI:0000 0001 2198 6209)